Ayala Corp: Helping in Rapid Ramp up of the Philippines' Test Trace and Treat (T3) Custom Case Solution & Analysis

1. Evidence Brief

Financial Metrics

Initial Testing Capacity: Approximately 2,000 to 3,000 tests per day in early April 2020.
Target Testing Capacity: 30,000 tests per day by May 30, 2020.
Actual Achievement: Testing capacity exceeded 30,000 per day by mid-year, with a total of 1.2 million tests conducted by July 2020.
Ayala Group Commitment: Allocated 2.4 billion pesos for internal COVID-19 response, including employee wage support and rent waivers for mall tenants.
Laboratory Costs: Individual molecular laboratory setup estimated between 15 million to 20 million pesos per facility.

Operational Facts

The T3 Framework: A public-private partnership focused on three pillars: Test (expanding lab capacity), Trace (digital and manual tracking), and Treat (increasing bed capacity and isolation units).
Infrastructure: Ayala transformed the World Trade Center in Pasay City into a 502-bed quarantine facility within seven days.
Supply Chain: Procured 250,000 RT-PCR test kits and 400,000 rapid test kits through global sourcing channels.
Lab Expansion: Increased the number of licensed testing labs from 1 in February 2020 to over 70 by July 2020.
Data Management: Developed a centralized dashboard to track real-time testing data, inventory levels, and hospital bed occupancy.

Stakeholder Positions

Jaime Augusto Zobel de Ayala (JAZA): Chairman of Ayala Corp. Position: Private sector must lead the resource mobilization because the government lacks the procurement agility required for a pandemic.
Secretary Vince Dizon: Presidential Adviser for Flagship Programs and Projects. Position: The government requires private sector logistics and project management to bypass bureaucratic bottlenecks.
Bill Luz: Private Sector Lead for T3. Position: Success depends on a data-driven approach and breaking down silos between rival private conglomerates.
Department of Health (DOH): Faced criticism for slow accreditation processes and manual data reporting.

Information Gaps

Specific unit costs for test kits procured via the private sector versus government-negotiated prices.
Long-term maintenance plans for the molecular labs once the immediate pandemic crisis subsides.
Detailed breakdown of the tracing pillar success rates compared to the testing and treatment pillars.

2. Strategic Analysis

Core Strategic Question

How can Ayala Corp utilize its operational expertise to bridge state capacity gaps during a national crisis while mitigating the risks of institutional overreach and political exposure?

Structural Analysis

The Philippine healthcare landscape in 2020 was defined by a fragmented delivery system and a centralized regulatory bottleneck at the Research Institute for Tropical Medicine (RITM). Using a Value Chain Analysis, the primary breakdown occurred in Inbound Logistics (kit procurement) and Operations (lab processing). The government possessed the mandate but lacked the supply chain agility. Ayala Corp operated as a Strategic Orchestrator, applying private sector logistics to a public sector failure.

Strategic Options

Option 1: The Orchestrator Model (Task Force T3)
Collaborate with the government and competitors to build a unified response structure. Rationale: Distributes financial burden and political risk while maximizing reach. Trade-offs: Requires high coordination effort; potential for brand dilution among many partners. Resources: Executive time, logistics networks, and existing government relations.

Option 2: Direct Infrastructure Provision
Build and operate proprietary Ayala healthcare facilities to serve the public. Rationale: Full control over quality and speed. Trade-offs: High capital expenditure; creates a long-term liability on the balance sheet for a temporary crisis. Resources: Real estate, construction teams, and specialized medical staff.

Option 3: Pure Philanthropic Funding
Donate capital to the DOH and Red Cross without operational involvement. Rationale: Low execution risk; clears the company of operational failure. Trade-offs: High probability of capital waste due to existing government inefficiency. Resources: Cash reserves only.

Preliminary Recommendation

Ayala should pursue Option 1. The Philippine government’s core weakness is not a lack of funds, but an inability to execute complex logistics under pressure. By leading Task Force T3, Ayala provides the missing operational layer without assuming the permanent costs of public health infrastructure. This model secures the national economy—and by extension, Ayala’s diversified business interests—faster than any other approach.

3. Implementation Roadmap

Critical Path

Week 1-2: Accreditation Fast-Track. Embed private sector specialists within the DOH to streamline the seven-step lab licensing process without compromising safety standards.
Week 3-6: Supply Chain Stabilization. Establish a centralized procurement office to aggregate demand for PCR kits, bypassing the 60% price markup observed in fragmented purchasing.
Week 7-12: Data Integration. Deploy a unified digital reporting system to replace manual encoding, reducing the data lag from 4 days to near real-time.

Key Constraints

Regulatory Friction: The DOH’s historical adherence to slow-moving protocols threatens the 30,000-test-per-day target.
Global Competition: Severe shortages of reagents and swabs as larger economies outbid the Philippines on the global market.
Talent Scarcity: A limited pool of licensed medical technologists capable of operating molecular laboratories.

Risk-Adjusted Implementation Strategy

To mitigate the risk of regulatory delays, the plan adopts a Parallel Processing Strategy. Construction of labs must begin simultaneously with the accreditation application, rather than sequentially. To address the reagent shortage, the procurement team will diversify sources across three geographic regions (South Korea, China, and Europe) to prevent a single-point failure in the supply chain. Contingency funds are allocated to fly in medical equipment via private charter if commercial cargo routes remain suspended.

4. Executive Review and BLUF

BLUF

Ayala Corp must lead Task Force T3. The Philippine government lacks the procurement agility and logistical precision required to prevent total economic stagnation. Ayala is not merely performing a social service; it is protecting the underlying macro environment that sustains its core banking, real estate, and telecommunications assets. The strategy must focus on removing the DOH accreditation bottleneck and centralizing the supply chain. Success will be measured by the 30,000-test-per-day threshold, which is the minimum requirement for a safe economic reopening. Failure to intervene guarantees a prolonged lockdown, eroding the group’s valuation across all sectors.

Dangerous Assumption

The analysis assumes the Philippine government will maintain its willingness to cede operational control to the private sector once the initial panic subsides. Bureaucratic inertia and political sensitivities regarding private sector involvement in public health could lead to the sudden re-imposition of restrictive regulations, stalling the expansion of testing capacity mid-stream.

Unaddressed Risks

Reputational Contagion: If a T3-partnered lab produces significant false positives or suffers a data breach, Ayala will bear the brand damage despite not having direct operational oversight of every facility.
Fiscal Sustainability: The plan relies on private donations that may dry up if the economic downturn lasts beyond two quarters, leaving the infrastructure half-completed or underfunded.

Unconsidered Alternative

The team did not evaluate a Digital-First Tracing Strategy. While testing and treatment are capital-intensive, a mobile-first tracing solution utilizing Ayala’s telecommunications arm (Globe) could have achieved higher containment rates at a fraction of the cost of building molecular labs. This would have shifted the focus from identifying the sick to preventing the spread, potentially reducing the total testing volume required.